Lymphatic metastases from pelvic tumors: Anatomic classification, characterization, and staging

Radiology

Volumn 254, Issue 1, 2010, Pages 31-46

  McMahon, Colm J ^a   Rofsky, Neil M ^a   Pedrosa, Ivan ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ANUS CARCINOMA; BLADDER CARCINOMA; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ENDOMETRIUM CARCINOMA; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; PELVIS TUMOR; PENIS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECTUM CARCINOMA; REVIEW; TESTIS CARCINOMA; TUMOR CLASSIFICATION; UTERINE CERVIX CARCINOMA; VAGINA CARCINOMA; VULVA CARCINOMA; HISTOLOGY; LYMPH NODE; NOMENCLATURE; PATHOLOGY; PELVIS; PROGNOSIS; THREE DIMENSIONAL IMAGING;

CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; IMAGING, THREE-DIMENSIONAL; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; PELVIC NEOPLASMS; PELVIS; PROGNOSIS; TERMINOLOGY AS TOPIC;

EID: 75349101061     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2541090361     Document Type: Review

References (98)

1. Pepper MS, Tille JC, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res 2003;314:167-177.
2. Hartveit E. Attenuated cells in breast stroma: the missing lymphatic system of the breast. Histopathology 1990;16:533-543.
3. Weiss L, Schmid-Schonbein GW. Biomechanical interactions of cancer cells with the microvasculature during metastasis. Cell Biophys 1989;14:187-215.
4. Fukunaga S, Maeda K, Noda E, Inoue T, Wada K, Hirakawa K. Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology 2006;71:204-211.
5. Kazama S, Watanabe T, Kanazawa T, Hatano K, Nagawa H. Vascular endothelial growth factor-C (VEGF-C) is a more specific risk factor for lymph node metastasis than VEGF-D in submucosal colorectal cancer. Hepatogastroenterology 2007;54:71-76.
6. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2005;11:8364-8371.
7. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002;161:947-956.
8. Gray H. The lymphatics of the abdomen and pelvis. In: Gray's Anatomy. 20th ed. Bartleby.com. http://www.bartleby.com/107/180.html., 1918.
9. Koh DM, Hughes M, Husband JE. Cross-sectional imaging of nodal metastases in the abdomen and pelvis. Abdom Imaging 2006;31:632-643.
10. Park JM, Charnsangavej C, Yoshimitsu K, Herron DH, Robinson TJ, Wallace S. Pathways of nodal metastasis from pelvic tumors: CT demonstration. RadioGraphics 1994;14:1309-1321.
11. Saksena MA, Kim JY, Harisinghani MG. Nodal staging in genitourinary cancers. Abdom Imaging 2006;31:644-651.
12. Walsh JW, Amendola MA, Konerding KF, Tisnado J, Hazra TA. Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease. Radiology 1980;137:157-166.
13. Vinnicombe SJ, Norman AR, Nicolson V, Husband JE. Normal pelvic lymph nodes: evaluation with CT after bipedal lymphangiography. Radiology 1995;194(2):349-355.
14. Grubnic S, Vinnicombe SJ, Norman AR, Husband JE. MR evaluation of normal retroperitoneal and pelvic lymph nodes. Clin Radiol 2002;57:193-200; discussion 201-204.
15. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997;169:521-525.
16. Oyen RH, Van Poppel HP, Ameye FE, Van de Voorde WA, Baert AL, Baert LV. Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994;190:315-322.
17. Fukuda H, Nakagawa T, Shibuya H. Metastases to pelvic lymph nodes from carcinoma in the pelvic cavity: diagnosis using thin-section CT. Clin Radiol 1999;54:237-242.
18. Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatialresolution MR imaging with histopathologic comparison. Radiology 2003;227:371-377.
19. Grey AC, Carrington BM, Hulse PA, Swindell R, Yates W. Magnetic resonance appearance of normal inguinal nodes. Clin Radiol 2000;55:124-130.
20. Bipat S, Fransen GA, Spijkerboer AM, et al. Is there a role for magnetic resonance imaging in the evaluation of inguinal lymph node metastases in patients with vulva carcinoma? Gynecol Oncol 2006;103:1001-1006.
21. Fukuya T, Honda H, Hayashi T, et al. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 1995;197:705-711.
22. Yang WT, Lam WW, Yu MY, Cheung TH, Metreweli C. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR Am J Roentgenol 2000;175:759-766.
23. UICC-International Union against Cancer. TNM classification of malignant tumours. International Union against Cancer. http://www.uicc.org/index.php? option=com-content&task=view&id=14275&Itemid=197. Published 2008. Accessed December 16, 2008.
24. American Joint Committee on Cancer. AJCC cancer staging manual. New York, NY: Springer-Verlag, 2002.
25. Kuehn PG, Eisenberg H, Reed JF. Epidermoid carcinoma of the perianal skin and anal canal. Cancer 1968;22:932-938.
26. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984;54:114-125.
27. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 2001;92:77-84.
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: V.2.2008. 2008. http://www.nccn.org/professionals/physician-gls/ PDF/rectal.pdf. Accessed September 1, 2008.
29. Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study-a single center experience. J Urol 2004;172:1818-1821.
30. Vieweg J, Gschwend JE, Herr HW, Fair WR. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449-454.
31. Vazina A, Dugi D, Shariat SF, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol 2004;171:1830-1834.
32. Herr HW. Routine CT scan in cystectomy patients: does it change management? Urology 1996;47:324-325. [Published correction appears in Urology 1996;47(3):785.]
33. Simms MS, Mann G, Kockelbergh RC, Mellon JK. The management of lymph node metastasis from bladder cancer. Eur J Surg Oncol 2005;31:348-356.
34. Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19-23.
35. Frank I, Cheville JC, Blute ML, et al. Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy: clinicopathologic features associated with outcome. Cancer 2003;97:2425-2431.
36. Kassouf W, Agarwal PK, Herr HW, et al. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 2008;26:121-126.
37. Sakuragi N, Satoh C, Takeda N, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 1999;85:1547-1554.
38. Lee JM, Lee KB, Lee SK, Park CY. Pattern of lymph node metastasis and the optimal extent of pelvic lymphadenectomy in FIGO stage IB cervical cancer. J Obstet Gynaecol Res 2007;33:288-293.
39. Puente R, Guzman S, Israel E, Poblete MT. Do the pelvic lymph nodes predict the parametrial status in cervical cancer stages IB-IIA? Int J Gynecol Cancer 2004;14:832-840.
40. Pieterse QD, Kenter GG, Gaarenstroom KN, et al. The number of pelvic lymph nodes in the quality control and prognosis of radical hysterectomy for the treatment of cervical cancer. Eur J Surg Oncol 2007;33:216-221.
41. McMeekin DS, Lashbrook D, Gold M, et al. Nodal distribution and its significance in FIGO stage IIIc endometrial cancer. Gynecol Oncol 2001;82:375-379.
42. Hirahatake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:82-87.
43. Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer 2008;18:269-273.
44. Lutman CV, Havrilesky LJ, Cragun JM, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006;102:92-97.
45. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer 2007;17:1238-1244.
46. Parazzini F, Valsecchi G, Bolis G, et al. Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survival. Gynecol Oncol 1999;74:7-11.
47. Pereira A, Magrina JF, Rey V, Cortes M, Magtibay PM. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 2007;105:604-608.
48. Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol 2001;80: 56-61.
49. di Re F, Baiocchi G, Fontanelli R, et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol Oncol 1996;62:360-365.
50. Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol 1999;73:237-241.
51. Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006;93:133-138.
52. Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol 2004;5:240-247.
53. Ficarra V, Zattoni F, Cunico SC, et al. Lymphatic and vascular embolizations are independent predictive variables of inguinal lymph node involvement in patients with squamous cell carcinoma of the penis: Gruppo Uro-Oncologico del Nord Est (Northeast Uro-Oncological Group) Penile Cancer data base data. Cancer 2005;103:2507-2516.
54. Singh I, Khaitan A. Current trends in the management of carcinoma penis-a review. Int Urol Nephrol 2003;35:215-225.
55. Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol 2007; 177:947-952;discussion 952.
56. Demkow T. The treatment of penile carcinoma: experience in 64 cases. Int Urol Nephrol 1999;31:525-531.
57. Lopes A, Hidalgo GS, Kowalski LP, Torloni H, Rossi BM, Fonseca FP. Prognostic factors in carcinoma of the penis: multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J Urol 1996;156:1637-1642.
58. Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005;173:816-819.
59. Weckermann D, Holl G, Dorn R, Wagner T, Harzmann R. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer. BJU Int 2007;99:1036-1040.
60. National Cancer Institute. National Cancer Institute Physician Data Query (PDQ). http://www.cancer.gov/cancertopics. Accessed October 14, 2008.
61. Engelen SM, Beets-Tan RG, Lahaye MJ, Kessels AG, Beets GL. Location of involved mesorectal and extramesorectal lymph nodes in patients with primary rectal cancer: preoperative assessment with MR imaging. Eur J Surg Oncol 2008;34:776-781.
62. Koh DM, Brown G, Temple L, et al. Distribution of mesorectal lymph nodes in rectal cancer: in vivo MR imaging compared with histopathological examination. Initial observations. Eur Radiol 2005;15:1650-1657.
63. Wang C, Zhou ZG, Yu YY, et al. Patterns of lateral pelvic lymph node metastases and micrometastases for patients with lower rectal cancer. Eur J Surg Oncol 2007;33:463-467.
64. Luna-Perez P, Corral P, Labastida S, Rodriguez-Coria D, Delgado S. Inguinal lymph node metastases from rectal adenocarcinoma. J Surg Oncol 1999;70:177-180.
65. Klein FA, Whitmore WF Jr, Sogani PC, Batata M, Fisher H, Herr HW. Inguinal lymph node metastases from germ cell testicular tumors. J Urol 1984;131:497-500.
66. Daugaard G, Karas V, Sommer P. Inguinal metastases from testicular cancer. BJU Int 2006;97:724-726.
67. Ray B, Hajdu SI, Whitmore WF Jr. Proceedings: Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 1974;33:340-348.
68. Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-1399.
69. Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol 2006;176:100-103;discussion 103-104.
70. Al-Kurdi M, Monaghan JM. Thirty-two years experience in management of primary tumours of the vagina. Br J Obstet Gynaecol 1981;88:1145-1150.
71. Rosen C, Malmstrom H. Invasive cancer of the vulva. Gynecol Oncol 1997;65:213-217.
72. Bafna UD, Devi UM, Naik KA, Hazra S, Sushma N, Babu N. Carcinoma of the vulva: a retrospective review of 37 cases at a regional cancer centre in South India. J Obstet Gynaecol 2004;24:403-407.
73. Paladini D, Cross P, Lopes A, Monaghan JM. Prognostic significance of lymph node variables in squamous cell carcinoma of the vulva. Cancer 1994;74:2491-2496.
74. Moore RG, DePasquale SE, Steinhoff MM, et al. Sentinel node identification and the ability to detect metastatic tumor to inguinal lymph nodes in squamous cell cancer of the vulva. Gynecol Oncol 2003;89:475-479.
75. Sodee DB, Sodee AE, Bakale G. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007;37:17-28.
76. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.
77. Williams AD, Cousins C, Soutter WP, et al. Detection of pelvic lymph node metas tases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography. AJR Am J Roentgenol 2001;177:343-348.
78. Sanz G, Robles JE, Gimenez M, et al. Positron emission tomography with 18fluorinelabelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999;84:1028-1031.
79. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322-1328.
80. Albrecht S, Buchegger F, Soloviev D, et al. (11)C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging 2007;34:185-196.
81. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331-335.
82. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with 11Cacetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607-611.
83. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-1419.
84. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-186.
85. Schilling D, Schlemmer HP, Wagner PH, et al. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int 2008;102:446-451.
86. Choi HJ, Roh JW, Seo SS, et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/ computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 2006;106:914-922.
87. Horowitz NS, Dehdashti F, Herzog TJ, et al. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546-551.
88. Kitajima K, Murakami K, Yamasaki E, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008;190:1652-1658.
89. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001;218:776-782.
90. Weissleder R, Elizondo G, Wittenberg J, Rabito CA, Bengele HH, Josephson L. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.
91. Harisinghani MG, Saini S, Weissleder R, et al. MR lymphangiography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR Am J Roentgenol 1999;172:1347-1351.
92. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med 2004;45:1509-1518.
93. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings - initial observations. Radiology 2004;231:91-99.
94. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005;23:2813-2821.
95. Heesakkers RA, Hovels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9:850-856.
96. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005;66:1066-1071.
97. Deserno WM, Harisinghani MG, Taupitz M, et al. Urinary bladder cancer:preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233:449-456.
98. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 2006;7:52-60.